2011 Gain: $32.87 (60%) 2011 Closing price: $87.61 Last year, investors turned away from HMO stocks such as this, fearing the impact of a new health care overhaul rule involving medical-loss ratios. However, Humana showed it was able to manage the new regulation and in October delivered better-than-expected profits and a better-than-expected forecast for 2012. Stephen Weiss, partner at Short Hills Capital, “At eight times earnings, you’re owning a stock that’s still cheap and very, very defensivPhoto: Humana.com – Advertisement – The FDA has 60 days to review the final submission, and after this, if the application is acceptable for review, a PDUFA goal date will be set. It should be noted that the drug was granted Breakthrough Therapy Designation (BTD) in 2019, reducing the review time from 10 months to 6 months.“We see scope for Provention to meet its prior guidance of a potential U.S. approval of teplizumab for the delay or prevention of T1D in at-risk individuals in mid-2021… Teplizumab is a potential breakthrough asset, with highly significant results in subjects ‘at-risk’ for end-stage T1D,” Amusa commented.Looking at the Phase 2 “at-risk” study, even though it’s smaller in size, the data represents the “first demonstration of therapeutic modulation of disease progression in T1D, strongly supporting Provention’s approach to treating autoimmune disease in the early stages,” in Amusa’s opinion. In addition, the therapy was praised in an editorial published in the New England Journal of Medicine.What’s more, Amusa estimates the at-risk population is a blockbuster opportunity just in the U.S. Based on information from the JDRF T1 Fund, there are over 300,000 stage 1-2 T1D patients in the U.S. and 2.3 million worldwide. “300,000 U.S. patients at a $60,000 one-time price for a course of treatment implies a $18 billion total market opportunity. A 60,000 per year transitioning population for each stage implies a $2.4 billion per year recurring total market opportunity,” he explained.Taking the #99 spot on TipRanks’ ranking, Amusa is currently tracking a 31.8% average return per rating.FabrinetFabrinet has just received a thumbs up from Needham’s Alex Henderson, with this five-star analyst putting an $85 price target (29% upside potential) and a buy rating on the stock on November 3.In the most recent quarter, the optical communications device company handily beat Henderson’s revenue and EPS estimates by 4.4% and 7%, respectively, and posted year-over-year growth of 9.4% and 22.9%, respectively. All of this was achieved despite an uncertain backdrop, with pressure on Huawei and Service Provider spending also reflected. Putting it simply, Henderson said, “These are good results.”Henderson argues that investors have been waiting to see Huawei’s impact fall out of its numbers, and now that the “fourth quarter bridge has been crossed, the upside is all that remains.”Cisco is moving a large portion of Systems products to Fabrinet, which could exceed $250 million annually, according to Henderson. However, he points out that the reported numbers only reflect a minor contribution from the Cisco transition, but this should really ramp in CYQ1 2021 and reach full run rate by June, with the first full quarter run rate expected in September.The analyst further mentioned, “We think the scale of this additional business is generally not reflected in the outlook and Street estimates… It should add at least $50-$60 million to Revenues year-over-year. The Street estimates have CYQ3 Revenues at $454 million up $18 million. We think the Fabrinet without Cisco could hit this number. If the rest of FN was flat it would do $486-$496 million. That’s a lot of upside.”TipRanks shows that the #153-rated analyst scores a 57% success rate and a 20.4% average return per rating.LivePersonSince CFO John Collins came on board, business messaging and communications software company LivePerson has placed a significant focus on implementing a data-driven approach across all aspects of the business, giving five-star analyst Ryan MacDonald, of Needham, “increased confidence in the improving trajectory of the business.”Taking an even more bullish stance, on October 30, MacDonald increased the price target from $60 to $65, in addition to reiterating a Buy rating. The new price target puts the upside potential at 5%.Based on the results from its third quarter, MacDonald argues the data-driven approach appears to be working. The company delivered a “Rule of 40 with a combination of 26% revenue growth and 18% free cash flow margin.” This marked LPSN’s first quarter of positive free cash flow since Q4 2018, with it highlighting “the progress the company is making on expense optimization while producing strong top line growth,” in the analyst’s opinion.“LPSN is adamant that the pandemic-driven increases in usage are sustainable and indicative of a structural shift in the market… When combining this with the operational efficiencies that the company is implementing across the organization, we remain confident that LPSN can continue to accelerate growth and expand margins,” MacDonald commented.Some investors expressed concern that new logos have yet to rebound. However, MacDonald believes there is a “strong near-term expansion opportunity in the existing base can support growth acceleration while new reps and channel partners ramp.” As a result, he is a buyer at current levels.Given MacDonald’s 81% success rate and 40.4% average return per rating, he is among TipRanks’ Top 45 best-performing analysts.QualcommOn November 4, Deutsche Bank’s Ross Seymore maintained a buy rating on Qualcomm following a beat and raise quarter for the semiconductor company. Reflecting an additional bullish signal, the five-star analyst boosted the stock price forecast from $127 to $150, implying upside potential of 16%.Shares of Qualcomm surged over 11% in after-hours trading in response to the print. Looking at the details, it reported fiscal Q4 revenue of $6.5 billion, up 33% quarter-over-quarter. The analysts were expecting revenue of $5.9 billion. Non-GAAP EPS of $1.45 beat the Street’s $1.17 call. Although gross margin declined by 60 basis points quarter-over-quarter to 58.7%, it exceeded the 58.1% consensus estimate.When it came to its guidance for the upcoming quarter, Qualcomm didn’t disappoint. Management expects revenue to be in the range of $7.8 billion-$8.6 billion, up 26.1% quarter-over-quarter at the $8.2 billion midpoint. This easily beat the $7.1 billion consensus estimate.According to management, the ramp of 5G networks and handsets drove the strong performance, with Qualcomm’s CEO stating that the results included a “partial quarter impact” from a large handset producer in the U.S.Based on this “strong beat/raise,” Seymore argues Qualcomm is the “premier way” to play the expansion set to take place in the 5G handset space over the next year.As the analyst boasts an 82% success rate and a 28% average return per rating, Seymore is Wall Street’s 24th best-performing analyst.HumanaFollowing Humana‘s strong Q3 performance, Oppenheimer’s Michael Wiederhorn continues to see the health insurance company as a compelling play in the space. Accordingly, the five-star analyst reiterated a buy rating and $460 price target (2% upside potential) on November 3.For Q3, adjusted EPS came in at $3.08, well ahead of the $2.80 consensus estimate. Additionally, utilization bounced back to 95% of historical baseline levels by the end of the quarter, with non-coronavirus utilization expected to remain below normal levels in Q4.Although HUM guided for a Q4 EPS loss of between $2.29-$2.54, this factors in its investments in the Medicare channel, with this area of the business reflecting a significant market opportunity, in Wiederhorn’s opinion. On top of this, given the potentially “more favorable reimbursement environment and the maturation of its high-growth member base,” HUM could drive an improvement in margins.“Given the attractive growth of the company’s Medicare Advantage (MA) business, we believe Humana should return significant returns to shareholders,” Wiederhorn noted.Management also mentioned that the recently issued 2022 proposed rate increase of 2.82% for MA will likely, “benefit the company similarly to the overall market,” adding that 92% of members are in 4+ Star plans.With a 75% success rate and 21% average return per rating, Wiederhorn lands within the Top 30 on TipRanks’ list of best-performing analysts. While it’s now becoming clear Joe Biden will take the White House, investors are betting that Congress will be split, leaving President Trump’s corporate tax policy unchanged.“Up until about last week, the consensus belief was a full blue sweep — now that’s changing you’re seeing a repricing taking place in the market… a more status quo Senate may ease the burden of regulations on the tech sector,” Anna Han, an equity strategist at Wells Fargo Securities, commented.That said, as many factors remain uncertain, finding stocks primed to outperform the broader market isn’t easy.- Advertisement – One approach is to look at the recent stock picks from analysts that consistently get it right. TipRanks analyst forecasting service attempts to identify Wall Street’s best-performing analysts, or the analysts with the highest success rate and average return per rating, tracked on a one-year basis.Here are the best-performing analysts’ five favorite stocks right now:Provention BioOn November 2, biotech company Provention Bio revealed the rolling submission of the BLA for teplizumab, a therapy that could potentially delay or prevent clinical type 1 diabetes (T1D) in at-risk patients, had been completed. For Chardan analyst Gbola Amusa, this development reaffirms his confidence in PRVB, with the company remaining a “Top Pick for 2020.” To this end, he reiterated a Buy rating and $35 price target (169% upside potential) after the news broke.- Advertisement – – Advertisement –
A package of tourist laws was also on the agenda of today’s session of the Parliament.The most important among them is certainly the proposal Of the Law on Tourist Boards and the Promotion of Croatian Tourism, which needs to be revised not only to implement the measures set out in the Tourism Development Strategy for the period until 2020, but also to increase its overall efficiency, especially at regional and local level, all to ensure preconditions for systematic implementation of destination management.The most important changes in the proposal of the mentioned law concern the establishment of the system of tourist boards according to the model of destination management organizations, in the sense that the tourist system is reorganized through merging and rationalization within the system with the application of the principle of financial self-sufficiency. For several units of local or regional self-government through the allocation of financial resources. Also, the tasks of tourist boards are redefined while respecting the principle of self-sufficiency, in such a way that the tasks of the local tourist board are defined exclusively as operational. , while the tasks of the regional tourist community are focused on operational activities, but with certain strategic elements through four basic groups of tasks: strategic planning and development, tourism system management, information and research, and marketing. The tasks of the CNTB, as a national tourism organization, are primarily focused on marketing and promoting tourism at the national level. Among the important changes contained in the draft law is the amendment limiting the share of members in the assembly to local tourist boards to 30% (instead of 40% so far), all in order to prevent individual entities from having the upper hand in decision-making.Proposal Law on membership fees in tourist boards contains novelties that will simplify the membership fee calculation process, and due to administrative relief and reduction of business costs create a better business environment. In particular, tourist classes are abolished, and consequently membership fee rates will not be determined depending on the tourist class. for the calculation of the membership fee from the current 28 to 5, the obligation to pay the membership fee is deleted for a part of the taxpayer, while the scope of payment of the same is reduced for a part of the taxpayer. Banks are also obliged to pay membership fees. Legal and natural persons operating in assisted areas (groups I-IV) will pay a membership fee reduced by 20%. It is also proposed a different distribution of tourist membership fees in such a way that regional tourist boards instead of the current 10% of the mentioned source of income will receive 15%, while the CNTB will receive 25% instead of the previous 20%. It is anticipated that these measures will relieve the economy of around HRK 11 million annually.Basic changes in the proposal Of the Tourist Tax Act relate to the decentralization of decision-making on the amount of tourist tax. Specifically, the amount of the tourist tax would no longer be determined by the Government of the Republic of Croatia, but by the county assemblies, ie the City Assembly of the City of Zagreb, while the Minister of Tourism would regulate only the minimum and maximum amount of the tourist tax. Among the most important innovations are those concerning the different distribution of tourist tax funds, so that regional tourist boards would receive 10% instead of the current 15%, while the CNTB would receive 25% of the total amount of the tax instead of the current 20%.You can see the whole presentation and discussion below in the attachment.In the meantime, there is no need to worry about it. ”
The veterinary staff of the Guyana Livestock Development Authority (GLDA) will be in Georgetown today to take blood samples from horses to test for Equine Infectious Anaemia (EIA), also known as swamp fever.In a social media post, the Agriculture Ministry said the disease was caused by a virus and was transmitted by blood-sucking insects.Further, the Ministry informed, “The horses from which samples will be taken will also be dewormed and given vitamins at no cost to the owner as part of this exercise.”The exercise will commence at 07:00h in central Georgetown and will wind down at 15:00h in Sophia, Greater Georgetown.Officials at the GLDA told Guyana Times that owners of horses had no reason to panic as there was no outbreak of the disease. It was explained that the project is part of the organisation’s animal health work programme for this year.Similar exercises were conducted from Turkeyen to Good Hope on the East Coast of Demerara and from Brickery to Ruimveldt on the East Bank of Demerara on June 18 and 20, respectively.EIA, or swamp fever, is also called horse malaria. The virus attacks the red blood cells of horses causing anaemia, weakness, and even death.Research shows that there is no cure for the disease, and horses are required to be tested regularly.Once a horse is infected, the virus remains in the animal’s body for the rest of its life.A few warning signs of the disease may include slight to high fever for a few days, weakness, weight loss, depression, and even disorientation.Persons with enquiries can contact the GLDA on 220-6556 or 220-6557 for more information.The sudden testing for these animals come at a time when the Trinidad and Tobago Government recently took a stance to ban all poultry items from Guyana after expressing concerns over duck viral hepatitis.A memo dated May 31, 2019, and signed by the twin-island republic’s Senior Veterinary Officer informed the Customs and Excise Division of the ban.The Agriculture Ministry had announced that the GLDA’s hatchery was closed owing to the unusual death of ducklings.“There is an increased mortality rate of ducklings being hatched at our facility; additionally, we were also informed by some farmers that a similar occurrence was taking place on a number of farms throughout the various regions,” the statement said.It was later mentioned that the Muscovy breed was under threat, especially those two to three weeks old. This precipitated surveillance and monitoring exercise targeting the animals. At that time, the deaths were labelled as an “unusual occurrence”.
May 24 2018Clear, plastic aligners have been growing in popularity as alternatives to bulky, metal braces. And once the teeth are straightened, patients graduate to plastic retainers to maintain the perfect smile. But these appliances can become contaminated, so one group is now reporting in ACS Applied Materials & Interfaces that they have developed a film to prevent bacteria from growing on them.According to the American Association of Orthodontists, more than 5 million people seek orthodontic treatments each year. These procedures include braces and aligners, a set of plastic pieces that shift the teeth slightly over time, in an attempt to fix crowded jaws, over- and under-bites and improperly aligned teeth. Clear aligners or retainers, known collectively as clear overlay appliances (COAs) are made by taking a dental cast and using pressure or heat on a plastic sheet. But bacteria frequently build up on COAs as difficult-to-treat biofilms, and the plastics easily wear down. Scientists have turned to developing simple and affordable coatings to combat this. Drawing inspiration from super-hydrophilic antibacterial coatings on other medical devices, Hyo-Won Ahn, Jinkee Hong and colleagues wanted to see if they could make something similar for COAs in the unique oral environment.The researchers took a polymer sheet made of polyethylene terephthalate that was modified with glycol (PETG) and layered films of carboxymethylcellulose and chitosan on it. This layered film created a super-hydrophilic surface, or a surface that loves water, that prevented bacteria from adhering. When PETG with the film was compared to the bare material, bacterial growth was reduced by 75 percent. The coated plastic also was stronger and more durable, even when tested with artificial saliva and various acidic solutions. Source:https://www.acs.org/